Rotavirus vaccines: entering a new stage of deployment
- 1 October 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 20 (5) , 501-507
- https://doi.org/10.1097/qco.0b013e3282a56ba0
Abstract
Rotavirus is the single most important cause of severe diarrhoea in infants and young children. This review provides updated information concerning three rotavirus vaccines that are being evaluated and introduced globally. Two large, phase III clinical trials, each involving more than 60,000 infants in both developing and developed countries, demonstrated that both RotaTeq (Merck & Co., Whitehouse Station, New Jersey, USA), the pentavalent human-bovine reassortant vaccine, and Rotarix (GlaxoSmithKine Biologicals, Rixensart, Belgium), the monovalent live-attenuated human rotavirus vaccine, are safe with respect to intussusception when the first dose is administered between 6 and 12 weeks of age, and that both vaccines are 90-95% efficacious in preventing severe rotavirus gastroenteritis including hospitalization. The bovine (UK)-human rotavirus reassortant tetravalent (BRV-TV) vaccine, developed at the National Institutes of Health (USA), was licensed for local production in several developing countries. Rotavirus vaccines are entering a new stage of deployment toward the goal of reducing morbidity and mortality attributed to rotavirus infection in developing countries, and hospitalizations and emergency visits caused by rotavirus in developed countries. High vaccine prices appear to offset cost savings, and may make policymakers even in wealthy countries hesitate to introduce a rotavirus vaccine into their childhood immunization programmes.Keywords
This publication has 30 references indexed in Scilit:
- Detection of G12 Human Rotaviruses in NepalEmerging Infectious Diseases, 2007
- Rhesus Rotavirus Vaccine Effectiveness and Factors Associated With Receipt of VaccineThe Pediatric Infectious Disease Journal, 2006
- Molecular Epidemiology of Rotavirus Diarrhea among Children and Adults in Nepal: Detection of G12 Strains with P[6] or P[8] and a G11P[25] StrainJournal of Clinical Microbiology, 2006
- Risk factors for intussusception in infants in Vietnam and Australia: Adenovirus implicated, but not rotavirusThe Journal of Pediatrics, 2006
- Changing pattern of human group A rotaviruses: Emergence of G12 as an important pathogen among children in eastern IndiaJournal of Clinical Virology, 2006
- Projected Cost‐Effectiveness of Rotavirus Vaccination for Children in AsiaThe Journal of Infectious Diseases, 2005
- A Hexavalent Human Rotavirus–Bovine Rotavirus (UK) Reassortant Vaccine Designed for Use in Developing Countries and Delivered in a Schedule with the Potential to Eliminate the Risk of IntussusceptionThe Journal of Infectious Diseases, 2005
- A high incidence of intussusception in Japan as studied in a sentinel hospital over a 25-year period (1978–2002)Epidemiology and Infection, 2005
- Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccineReviews in Medical Virology, 2004
- Possible Mechanisms of Protection Elicited by Candidate Rotavirus Vaccines as Determined with the Adult Mouse ModelViral Immunology, 2003